Skip to Main content Skip to Navigation
Journal articles

Low Percentage of Signal Regulatory Protein alpha/beta(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients

Abstract : An important goal for personalized treatment is predicting response to a particular therapeutic. A drawback of biological treatment is immunogenicity and the development of antibodies directed against the drug [anti-drug antibodies (ADA)], which are associated with a poorer clinical outcome. Here we set out to identify a predictive biomarker that discriminates rheumatoid arthritis (RA) patients who are more likely to develop ADA in response to adalimumab, a human monoclonal antibody against tumor necrosis factor (TNF)alpha. By taking advantage of an immune-phenotyping platform, LEGENDScreen (TM), we measured the expression of 332 cell surface markers on B and T cells in a cross-sectional adalimumab-treated RA patient cohort with a defined ADA response. The analysis revealed seven differentially expressed markers (DEMs) between the ADA(+) and ADA(-) patients. Validation of the DEMs in an independent prospective European cohort of adalimumab treated RA patients, revealed a significant and consistent reduced frequency of signal regulatory protein (SIRP)alpha/beta-expressing memory B cells in ADA(+ )vs. ADA(-) RA patients. We also assessed the predictive value of SIRP alpha/beta-expression in a longitudinal RA cohort prior to the initiation of adalimumab treatment. We show that a frequency of <9.4% of SIRP alpha/beta-expressing memory B cells predicts patients that will develop ADA, and consequentially fail to respond to treatment, with a receiver operating characteristic (ROC) area under the curve (AUC) score of 0.92. Thus, measuring the frequency of SIRP alpha/beta-expressing memory B cells in patients prior to adalimumab treatment may be clinically useful to identify a subgroup of active RA subjects who are going to develop an ADA response and not gain substantial clinical benefit from this treatment.
Document type :
Journal articles
Complete list of metadata

https://hal-cnrs.archives-ouvertes.fr/hal-03295377
Contributor : Colette Orange <>
Submitted on : Friday, September 10, 2021 - 10:56:44 AM
Last modification on : Wednesday, September 15, 2021 - 1:27:58 PM

File

pdf
Publisher files allowed on an open archive

Identifiers

Citation

Laura Magill, Marsilio Adriani, Veronique Berthou, Keguan Chen, Aude Gleizes, et al.. Low Percentage of Signal Regulatory Protein alpha/beta(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. Frontiers in Immunology, Frontiers, 2018, 9, ⟨10.3389/fimmu.2018.02865⟩. ⟨hal-03295377⟩

Share

Metrics

Record views

26

Files downloads

15